Veru Inc
Change company Symbol lookup
Select an option...
VERU Veru Inc
RVVTF Revive Therapeutics Ltd
AMD Advanced Micro Devices Inc
IDAI T Stamp Inc
VZ Verizon Communications Inc
CETX Cemtrex Inc
RNXT RenovoRx Inc
BNTX BioNTech SE
ARTW Art's Way Manufacturing Co Inc
ARIZU Arisz Acquisition Corp
Go

Consumer Staples : Personal Care Products | Small Cap Value
Company profile

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Price
Delayed
$1.30
Day's Change
0.015 (1.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
1.33
Day's Low
1.27
Volume
(Light)

Today's volume of 191,588 shares is on pace to be much lighter than VERU's 10-day average volume of 3,172,625 shares.

191,588
  • Prev Close
    1.28
  • Today's Open
    1.31
  • Day's Range
    1.27-1.33
  • Avg Vol (10-day)
    3.2M
  • Last (time)
    10:29a ET 03/28/23
  • Last (size)
    100
  • 52-Wk Range
    1.25 - 24.55
    LowHigh
  • (08/17/22 - 03/24/23)
    3.48%
  • 185.5%
  • Market Cap
    104.5M
  • Shares Outstanding
    80.7M
  • -1.42
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • -0.1
  • 48.08
  • (% of float 02/28/23)
    25.80

Latest News

March 17, 2023
5:00 pm ET
Globe Newswire
March 14, 2023
8:10 am ET
Accesswire
March 13, 2023
2:06 pm ET
Globe Newswire
March 07, 2023
8:30 am ET
Globe Newswire
March 03, 2023
10:07 am ET
MarketWatch
7:01 am ET
MarketWatch
March 02, 2023
4:01 pm ET
Globe Newswire
February 24, 2023
10:37 am ET
Globe Newswire
February 21, 2023
7:15 am ET
Globe Newswire
February 14, 2023
7:26 am ET
MarketWatch
February 09, 2023
6:30 am ET
Globe Newswire
February 06, 2023
10:00 am ET
Globe Newswire
February 04, 2023
6:25 pm ET
Globe Newswire
10:48 am ET
Accesswire
February 03, 2023
1:42 pm ET
Globe Newswire
February 02, 2023
9:01 am ET
Accesswire
8:45 am ET
Newsfile
February 01, 2023
9:00 pm ET
BusinessWire
12:30 pm ET
Accesswire
11:00 am ET
Globe Newswire
1:45 am ET
PR Newswire
January 31, 2023
6:05 pm ET
Newsfile
4:55 pm ET
Accesswire
4:30 pm ET
Accesswire
1:45 am ET
Globe Newswire
January 30, 2023
3:45 pm ET
Accesswire
2:15 pm ET
Globe Newswire
12:31 pm ET
Newsfile
6:32 am ET
PR Newswire
January 29, 2023
9:00 pm ET
Globe Newswire
4:37 pm ET
Globe Newswire
2:58 pm ET
Globe Newswire
January 27, 2023
7:28 pm ET
Newsfile
10:13 am ET
Newsfile
8:10 am ET
Newsfile
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.